COMP <GO>
BMRN vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
BioMarin Pharmaceutical Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BMRN 9
— ABBV 6
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: BMRN
LAST: $58.51 (+1.77%) • MKT CAP: $11.13B
options-implied-move
6.70%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMRN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMRN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.70% | 70.20% | +7.50 | BMRN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | 29.00% | -23.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 33.3x | -12.30 | BMRN | /valuation <GO> |
| Free Cash Flow Yield | 6.51% | 3.47% | +3.04 | BMRN | /fcf-yield <GO> |
| Operating Margin | 12.70% | 24.60% | -11.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 6.90% | +3.90 | BMRN | /net-margins <GO> |
| Revenue Growth (YoY) | 12.90% | 8.60% | +4.30 | BMRN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.57 | 5.33 | +0.24 | BMRN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | BMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.70% | 7.40% | -0.70 | BMRN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.5 | 72.8 | -18.26 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.15 | -0.20 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.8x | 113.1x | -86.30 | BMRN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $513.86B | -$502.73B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMRN REV | ABBV REV | BMRN GROSS % | ABBV GROSS % | BMRN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.22B | $61.16B | 77.7% | 70.2% | $725.0M | $17.82B |
| FY 2024 | $2.85B | $56.33B | 79.7% | 70.0% | $487.4M | $17.83B |
| FY 2023 | $2.42B | $54.32B | 44.0% | 44.0% | $50.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMRN // BETA 0.95
ABBV // BETA 1.15